Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recasimab
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Recasimab is a recombinant humanized monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). Developed by Junshi Biosciences, it is designed to treat primary hypercholesterolemia and mixed hyperlipidemia. By binding to PCSK9, recasimab prevents the degradation of low-density lipoprotein receptors (LDLR) on the surface of hepatocytes, thereby increasing the clearance of low-density lipoprotein cholesterol (LDL-C) from the bloodstream. The drug received approval from China's National Medical Products Administration (NMPA) in 2024. Beyond primary lipid disorders, it is being investigated in Phase 4 clinical trials to manage drug-induced hypercholesterolemia, specifically in patients receiving the ALK inhibitor lorlatinib for non-small cell lung cancer.
- Brand names
- Junshitan君适坦
- Other names
- anti-PCSK9 monoclonal antibody JS002anti-PCSK-9 monoclonal antibody JS002anti-PCSK 9 monoclonal antibody JS002
02
Targets
PCSK9 (Proprotein convertase subtilisin/kexin type 9)
Beyond the preview
Go deeper on recasimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recasimab.